She is 47, sleeping badly, more tired than she used to be, and somewhere along the way her interest in sex basically disappeared.
Work is busy. Life is busy. Maybe it’s perimenopause. Maybe it’s stress. So she brings it up at an appointment.
Her estrogen gets discussed. Progesterone comes up. Thyroid gets checked. Everything looks reasonably normal, and the conclusion is familiar: this is probably just midlife.
Maybe.
But testosterone is rarely the first hormone women think about, even though women produce it throughout adult life.
That does not mean every woman with fatigue, brain fog, low mood, or low libido needs testosterone. In fact, current evidence is much narrower than a lot of hormone marketing suggests.
Still, testosterone belongs in the female hormone conversation. Especially when sexual desire changes, menopause enters the picture, or the ovaries have been surgically removed.
The interesting part is figuring out when it actually matters.
Why Testosterone Isn’t Just a ‘Male Hormone’
Women produce and use testosterone too, just at substantially lower concentrations than men. The ovaries and adrenal glands contribute to androgen production, along with conversion of other hormones in peripheral tissues. Levels also change with age.
Research reviewed by the Endocrine Society found that circulating testosterone falls substantially during the early and middle reproductive years. Women in their 40s may have roughly half the circulating testosterone measured in women in their 20s. Interestingly, this decline appears to be more strongly associated with age itself than with natural menopause suddenly causing testosterone to fall off a cliff. That distinction matters.
Estrogen changes dramatically around menopause. Testosterone follows a somewhat different trajectory.
Surgery can change things more abruptly. When both ovaries are removed, testosterone levels tend to fall further because the ovaries continue contributing to androgen production even after menopause. Studies comparing women with natural menopause with women who have undergone bilateral oophorectomy have found significantly lower testosterone in the latter group.
And testosterone does have physiological roles in women. It interacts with androgen receptors in the brain, reproductive tissues, muscle, bone, and elsewhere.
But this is where we need to separate physiology from treatment claims. The fact that testosterone participates in muscle or brain biology does not automatically mean giving testosterone will fix fatigue, build muscle, improve mood, sharpen cognition, or make someone feel 25 again. Current clinical evidence is strongest in one particular area: sexual desire in appropriately selected women with hypoactive sexual desire disorder, or HSDD. That is much narrower than “testosterone makes women feel better.” It is also much more scientifically defensible.
The Symptoms Women Often Attribute to Something Else
Hormone symptoms have an annoying problem. They overlap with basically everything.
Persistent fatigue? Could be hormones. Could also be anemia, thyroid disease, poor sleep, depression, iron deficiency, medication effects, sleep apnea, nutritional issues, or simply being overextended for six straight months.
Brain fog is equally unhelpful as a diagnosis. So are changes in motivation or mood.
Then there is libido. A woman may notice that sexual interest has dropped dramatically even though nothing obvious has changed in her relationship. Or maybe things have changed.
Stress, medications, relationship dynamics, vaginal pain, menopause, mental health, and dozens of other factors can influence desire.
Which is why a low testosterone lab value cannot simply be matched to a symptom and declared the cause.
The Endocrine Society has specifically recommended against diagnosing a broad “androgen deficiency syndrome” in otherwise healthy women because there is no well-defined syndrome linking a particular testosterone level with a predictable set of symptoms.
That does not mean symptoms should be dismissed. Quite the opposite. If libido disappears, workouts suddenly feel harder, concentration is worse, and you generally do not feel like yourself, that deserves a proper look. It just deserves a better answer than “your testosterone must be low.”
Why Medicine Has Been Slow to Address Female Testosterone
There is a strange imbalance in hormone medicine. Everyone knows women have estrogen. Everyone knows men have testosterone. The biology has never been that neat, but medical treatment often followed the stereotype anyway.
Part of the problem is research.
Testosterone therapy has been studied far more extensively in men. Female testosterone concentrations are much lower and historically harder to measure accurately. There has also been considerable debate over what “low testosterone” actually means in women, because there is no validated blood cutoff that diagnoses HSDD or a general female testosterone-deficiency syndrome.
Then there is the drug-approval problem. In the United States, there is currently no FDA-approved testosterone product designed specifically for women. That creates an awkward situation.
Evidence supports testosterone therapy for certain women, but clinicians often have to prescribe an existing testosterone formulation off-label and adjust treatment to maintain female physiologic levels.
Historically, testosterone products for women have been developed elsewhere. Intrinsa, a testosterone patch, was approved in Europe for surgically menopausal women with HSDD but was later withdrawn commercially. The FDA did not approve it for the U.S. market.
That lack of a female-specific product probably helped keep testosterone on the margins of routine menopause care.
Then something important happened. A group of major medical societies looked at the evidence and tried to answer the question directly. The resulting Global Consensus Position Statement on Testosterone Therapy for Women made one conclusion particularly clear: the only evidence-based indication for testosterone therapy in women was treatment of HSDD in postmenopausal women after appropriate clinical assessment.
That statement was endorsed by the International Society for the Study of Women’s Sexual Health, the North American Menopause Society, the Endocrine Society, and several other professional organizations.
This gave testosterone therapy in women something it had been missing for a long time. A legitimate place in mainstream clinical guidance. Just not for everything.
What Modern Female Testosterone Therapy Looks Like
First, female testosterone therapy is not men’s TRT with a smaller syringe.
The goal is different.
Women naturally have much lower testosterone concentrations, and treatment should aim to keep levels within the physiological range seen in premenopausal women rather than pushing testosterone into male ranges.
That is extremely important. Too much testosterone can cause androgenic effects such as acne, increased facial or body hair, scalp hair thinning, and potentially voice changes or clitoral enlargement at excessive exposure. More testosterone is not more therapeutic. It is just more testosterone.
Compounded products exist as well, but major consensus guidance has been cautious about them because potency and quality can vary and they do not go through the same FDA approval process.
Pellets and injections are another important distinction. The 2019 Global Consensus specifically advised against formulations that produce supraphysiologic testosterone concentrations, including pellets and injections when they create levels above the normal female range. That does not mean an injectable formulation can never be prescribed in clinical practice. It means the formulation, amount, frequency, laboratory response, and resulting testosterone concentration matter enormously.
This is why physician-guided testosterone therapy for women through a licensed clinic becomes especially important when injectable testosterone is being considered. The entire point should be controlled female-range exposure with baseline evaluation and follow-up, not applying a scaled-down bodybuilding or male TRT protocol.
And testosterone should not automatically replace the rest of the menopause conversation. A woman dealing with hot flashes, night sweats, vaginal dryness, poor sleep, and low libido may need estrogen or progesterone considerations as well. Hormones do not operate in separate departments. Treatment should not either. Monitoring matters just as much.
Providers generally establish a baseline, reassess testosterone after treatment begins, look for signs of androgen excess, and repeat measurements periodically once therapy is stable.
If levels keep climbing outside the female physiologic range, that is not evidence that the treatment is “working really well.” It is a reason to reassess it.
The 2021 ISSWSH Clinical Practice Guideline and What It Means
In 2021, the International Society for the Study of Women’s Sexual Health got much more specific about where testosterone fits into women’s healthcare.
The ISSWSH Clinical Practice Guideline focused on systemic testosterone therapy for women with hypoactive sexual desire disorder, or HSDD.
And importantly, it did not suggest treating every woman with low libido or a low testosterone result.
ISSWSH recommends first looking at the bigger picture.
Relationship problems, mental health, medications, pain during sex, menopausal symptoms, and other medical issues can all affect desire. Testosterone becomes a treatment consideration when HSDD is causing distress and those other contributors do not adequately explain the problem.
The guideline found the strongest evidence for postmenopausal women, although it noted that limited data also support consideration in some late reproductive-age premenopausal women.
It also gave clinicians something female testosterone care had been missing for a long time: practical prescribing standards.
Before treatment, total testosterone and SHBG should be checked. Testosterone is then monitored after therapy begins, not because there is a magic level that treats HSDD, but to make sure concentrations stay within the normal physiological range for premenopausal women.
ISSWSH specifically says a total testosterone result should not be used to diagnose HSDD. The diagnosis is clinical. The lab work helps make treatment safer.
The guideline also favors transdermal testosterone when treatment is appropriate. Because there is no FDA-approved testosterone product for women in the United States, carefully adjusted male transdermal formulations may sometimes be prescribed off-label. ISSWSH does not recommend compounded testosterone products because of concerns about consistency and the lack of supporting efficacy and safety data.
And treatment should not continue indefinitely just because testosterone levels changed. The point is improvement in the symptom that led to treatment.
If sexual desire and associated distress do not improve after an adequate trial, the diagnosis and treatment plan should be reconsidered. That may be the most useful thing the 2021 guideline added to the conversation.
It treated testosterone therapy for women as legitimate medical care, but with a defined patient population, a specific treatment goal, and real monitoring rather than the vague idea that women simply need “more testosterone.”
What to Ask Your Provider About Testosterone Testing
Yes, testosterone can be tested in women. No, a low testosterone result by itself does not diagnose HSDD.
The 2019 consensus specifically states that there is no testosterone cutoff capable of separating women with normal sexual function from women with sexual dysfunction.
So why test it?
Because baseline testosterone can help establish whether treatment would risk pushing levels too high and gives the clinician something to monitor once therapy starts.
Total testosterone is generally the primary measurement used in current guidance. SHBG, or sex hormone-binding globulin, can also provide useful context because it affects how testosterone circulates and may influence interpretation of results. Free testosterone may sometimes be reported or calculated, although the Global Consensus cautions against treating it as a uniquely definitive measure of female androgen status. And female ranges are much lower than male ranges.
That matters enormously when somebody is prescribing a testosterone product originally manufactured for men.
If you are discussing testosterone with a provider, reasonable questions include:
- What is actually causing my symptoms?
- Are there other explanations we should rule out first?
- What is my total testosterone?
- Is SHBG relevant in my case?
- What symptom are we specifically trying to treat?
- Which formulation are you recommending, and why?
- How will we make sure my testosterone stays within a physiological female range?
- When will labs be repeated?
- And what happens if the symptom does not improve?
Those questions are far more useful than simply asking whether your testosterone is “optimal.”
The Hormone Conversation Needs More Nuance, Not More Hype
Women absolutely have testosterone.
Levels change with age, ovarian surgery can lower them further, and testosterone plays real physiological roles throughout the female body.
Medicine was slow to give that fact much attention. Now it is catching up.
But catching up does not mean turning testosterone into the explanation for every frustrating symptom of midlife.
The evidence is strongest for a specific problem: HSDD in appropriately evaluated women. That is enough to make testosterone worth talking about. Know what has changed. Know your labs. Ask what else could be contributing. And if testosterone treatment enters the conversation, make sure the goal is clear, and the monitoring is real.
Women deserve more than being told everything is “just aging.” They also deserve better than being told every problem is testosterone.
